Cypralis is focused on the discovery and development of highly innovative therapeutics for the modulation of peptidyl-prolyl isomerases (known as PPIases), a large family of druggable protein targets known to be involved in many acute and chronic diseases. More…
Pipeline
Cypralis’ pipeline includes novel medicines being developed for degenerative diseases such as Liver Disease, Acute Tissue Injury and Inflammation.
Technology
Cypralis is focused on the discovery and development of highly innovative therapeutics for the modulation of peptidyl-prolyl isomerases known as PPIases, a large druggable family of protein targets involved in many acute and chronic diseases.
Contact Us
Cypralis is seeking to establish collaborations with pharmaceutical and biotech companies to develop PPIase inhibitors for a number of diseases. Please contact us to explore the opportunities.